A Practical Framework for Pharmaceutical Regulatory Strategy
Turn Regulatory Uncertainty Into Defensible Development Decisions
Regulatory Affairs Development
Jason Morgan, Ph.D.A systematic framework for pharmaceutical development professionals to connect intended labeling, evidence, FDA questions, and strategic decisions.
A Framework Centered on the USPI for Claim Architecture, Evidence Sufficiency, FDA Questions, and Lifecycle Strategy

The regulatory strategy challenge
A development plan needs a defensible regulatory logic.
Development objectives, scientific and clinical evidence, regulatory requirements, and agency expectations must fit together. Unresolved assumptions can change the evidence needed, the labeling that is supportable, or the development paths still available.
Regulatory Affairs Development (RAD) organizes those connections around the target U.S. Prescribing Information (USPI). It links proposed claims to explicit requirements, mapped evidence, uncertainty, FDA interactions, and alternative strategies so that the reasoning behind a decision can be examined.
What readers will learn
Give complex regulatory questions a visible structure.
Move from a proposed product-use statement to the evidence, uncertainties, and choices that determine a regulatory strategy.
Start with the claim you need to support.
Use the target USPI to define proposed product-use statements, then map each claim to the standards, requirements, and evidence it depends on.
Distinguish evidence presence from evidence sufficiency.
Assess the mapped evidence against a requirement, keep assumptions visible, and review filing readiness separately from evidence strength.
Make FDA questions decision-relevant.
Connect agency interactions to specific uncertainties and examine whether new information could change a development commitment or labeling position.
Compare feasible strategies and preserve the reasoning.
Identify hard gates before weighing tradeoffs. Document alternatives, fallback positions, residual risk, and the conditions that would trigger reconsideration.
Inside the book
From claim architecture to lifecycle strategy.
Eight parts connect the core method to technical disciplines, worked applications, and governance. The scope is FDA-regulated human prescription drugs and biological products developed through IND, NDA, and BLA pathways.
Foundation
Chapters 1–3Core RAD Method
Chapters 4–7RAD Artifacts
Chapters 8–11Regulatory Decision Making
Chapters 12–15Development Lifecycle Application
Chapter 16Functional Application of RAD Across Technical Domains
Chapters 17–23RAD Case Studies and Worked Applications
Chapters 24–31Operating Model and Testing
Chapters 32–34View all 34 chapter titles
I. Foundation
- Claim Architecture in Regulatory Affairs
- The USPI as the Product-Use Claim Specification
- Source Hierarchy and Regulatory Force
II. Core RAD Method
- Label Language and Claims
- Claims and Requirements
- Requirements and Evidence Sufficiency
- Reviewability and Filing Readiness
III. RAD Artifacts
- The USPI Claim-to-Evidence Traceability Matrix
- The Requirement Register
- The Assumption Register
- The Label Fallback Map
IV. Regulatory Decision Making
- The Unified RAD Mathematical Framework
- Probability and Decision Making Under Regulatory Uncertainty
- FDA Questions as Value of Information Instruments
- Strategy Selection, Hard Gates, and Pareto Tradeoffs
V. Development Lifecycle Application
- RAD Across FDA Product Development
VI. Functional Application of RAD Across Technical Domains
- Clinical RAD
- Statistical RAD
- Safety RAD
- Clinical Pharmacology RAD
- CMC RAD
- Labeling RAD
- Integrating Domain Inputs into a Single Regulatory Position
VII. RAD Case Studies and Worked Applications
- Reading FDA Review Documents Through a RAD Lens
- Flagship Case Study: Eteplirsen Claim Evolution
- Case Study 2: Benefit-Risk Under Residual Uncertainty
- Case Study 3: Safety Risk, Labeling, and REMS
- Case Study 4: Dose Justification and Exposure-Response
- Case Study 5: CMC Readiness as a Claim Enabler
- Running Worked Example: Drug X from Target USPI to FDA Questions
- The RAD Governance Memo
VIII. Operating Model and Testing
- Matrixed RAD Governance
- Testing and Validation Program
- Conclusion
Work through the questions behind the plan.
The running fictional Drug X example follows a target USPI through claim architecture, evidence assessment, FDA question strategy, and a governance recommendation. A separate eteplirsen case study examines claim evolution.
- What must the evidence support for the proposed label language to be defensible?
- Which unresolved FDA question could change a development decision?
- Which alternative labeling position remains supportable if the preferred claim fails?
Read an excerpt · How RAD Works
RAD begins with proposed label language, moves through a controlled sponsor decision, and repeats when new evidence, FDA feedback, or product changes alter the regulatory state. It is a sponsor decision loop in which each material update can change the claim architecture and the next action.
RAD is a sponsor-defined framework. Its scores and thresholds are internal decision controls; external validation remains to be established. FDA decisions remain governed by applicable legal standards, the scientific record, and review judgment.
Who should read this book?
For professionals making and supporting development decisions.
- Regulatory affairs professionals
- Connect regulatory requirements and advice to the claims and evidence behind a development plan.
- Pharmaceutical and biotechnology development teams
- Bring scientific, clinical, statistical, safety, and CMC inputs into a shared regulatory position.
- Regulatory strategy leaders
- Review feasible options, unresolved assumptions, and the reasoning behind major commitments.
- Clinical development professionals
- Relate study design and evidence generation to intended labeling and regulatory planning.
- Regulatory consultants
- Structure recommendations so that clients can examine the evidence, alternatives, and decision rationale.

Regulatory Affairs Development · Jason Morgan, Ph.D.
A More Structured Approach to Regulatory Strategy
Explore a practical framework for evaluating regulatory considerations, navigating uncertainty, and developing more defensible strategic decisions.
Get the Book on Amazon (opens in a new tab)